dokumendiregister.ee
OtsingAsutusedMCP
Otsing›Sotsiaalministeerium
Muu lepingAvalik

European Joint Programme on Rare Diseases 2019.a. projektide taotlusvooru leping

Sotsiaalministeerium · 7. aprill 2020
Viit
1.8-2/772-2
Registreeritud
7. aprill 2020
Dokumendi liik
Muu leping
Funktsioon
1.8 Finantsplaneerimine ja raamatupidamisarvestus
Sari
1.8-2 Lepingud (töövõtt ja käsundus juriidiliste isikutega, koostöölepe kulude hüvitamiseks, haldus, liising, üür-rent, kindlustus, müük, litsentsid, ost, varaline vastutus, varakasutus, andmevahetus) koos aktidega
Toimik
1.8-2/2024
Vastutaja
Mari Teesalu (Sotsiaalministeerium, Kantsleri vastutusvaldkond, e-teenuste asekantsleri vastutusvaldkond, Analüüsi ja statistika osakond)

Failid

  • 📎1.8-2772-2 07.04.2020 Muu leping (2).bdoc1725 KB

Sisu (failidest)

PROJEKTI 'Suurte sarkomeeriliste geenide diagnostilise efektiivsuse suurendamine.' ANDMETE KAART ÜLDANDMED Projekti etapp Projekti tüüp leping Toetus -> Teadusprojekt Projekti nimetus (eesti keeles) Projekti lisatingimused Suurte sarkomeeriliste geenide diagnostilise efektiivsuse suurendamine. Projekti nimetus (inglise keeles) Improved diagnostic output in large sarcomeric genes Ülikoolile laekuv summa: 75000,00 Projekti akronüüm IDOLS-G Projekti kogumaht TÜ-s: 75000,00 Projekti eeldatav kestus: Üldkulu eraldis: 15000,00 20,00% 10.03.2020 - 28.02.2023 Vastutav täitja: Katrin Õunap (MVCM18 kliinilise geneetika professor) Projektijuht: Kerli Meister (MVCM juhiabi) Koordinaator: Laura Tomson (P1GY03 välisrahastuse koordinaator) Projekti link rahaveebi: https://www.is.ut.ee/pls/ois_sso/!tere.tulemast?leht=RV.RV.EL&fin_allika_koodi_ osa=&naita_ka_passiivseid=1 Projekti staatus: koostamisel Rahastajad: Sotsiaalministeerium, Angela Ivask Taotletud summa: 75000,00 Saadud summa: 75000,00 Rahastusprogramm: Horisont 2020 programm Kokku: 75000,00 Omafinantseeringud: Mitteabikõlblike kulude finantsallikad: GMVCM0471PR Käsutaja: Katrin Õunap Finantsallikas: Aruande tähtajad: Abikõlblikkuse periood: Raamatupidaja: 10.03.2020 - 28.02.2023 Liigitus: Sotsiaalministeerium: Välisrahastus -> Muu välisrahastus Annotatsioon eesti keeles: Kaasasündinud müopaatiad on pärilikud haigused, mille korral on kahjustatud perifeersed skeletilihased (SMD). SMD on väga suur grupp pärilikke lihashaigusi, mis võivad olla väga erineva algusaja, progresseerumise ja lihaste haaratusega. Selline suur SMD-de kliiniline variaabelsus ja kindla genotüüüp-fenotüüp korrelatsiooni puudumine ning nendega seotud geenide (eriti TTN ja NEB) suurus teeb diagnostilise protsessi väga keeruliseks. Ligikaudu pooled SMD patsiendid ei oma molekulaarset diagnoosi sõltumata intensiivsest uurimisprotokollist, mis sisaldab kliinilist, histoloogilist, radioloogilist ja geneetilist testimist. SMD-de molekulaarne diagnoos on vajalik optimaalse ravi, korrektse prognoosi ja täpse geneetilise nõustamise teostamiseks. Ka ei ole teada TTN ja NEB geeni funktsionaalsed mõjud inimese organismile. Antud projekt toob esile sünergistliku koostöö klinitsistide, geneetikute, patoloogide, füsioloogide, biofüüsikute ja patsientide organisatsioonide vahel. Eesmärk on parandada diagnostilist töövoogu skeletilihaste haigustele, mis on tingitud suurtes - TTN (titin) ja NEB (nebulin) esinevatest muutustest kasutades nende uurimiseks uudseid tehnoloogiaid (5 tööpaketti). Meie eesmärgiks on disainida ja valideerida uued töömeetodid, mis saaksid kasutusele võetud suurtes klinitsistide ja teadlaste gruppides, kes töötavad selliste haigustega ning iseloomustada funktsionaalselt genotüüp fenotüüp korrelatsioone antud haiguste korral. Annotatsioon inglise keeles: Inherited myopathies are genetically determined diseases affecting voluntary muscles (skeletal muscle disorders or SMDs). SMDs include a wide spectrum of disorders characterized by a different age of onset, disease progression, and muscle involvement. The phenotypic variability seen in SMDs, the lack of clear-cut genotype- phenotype correlations and the sheere size of the SMD- associated genes (e.g., TTN or NEB) make the diagnostic process complex. Half of the patients do not receive a molecular diagnosis despite a workflow including clinical, histological, imaging and genetic tests. The molecular diagnosis is crucial for SMD patients in order to receive optimal care, correct prognosis and proper genetic counceling. Futhermore, the functional consequences of the genetic variations in these genes are nearly unknown. This project, which brings to life a synergistic cooperation between clinicians, geneticists, pathologists, physiologists, biophysicists and patient advocacy organizations, aims at improving the diagnostic pipeline for skeletal muscle disorders caused by mutations in large genes like TTN (titin) and NEB (nebulin), using novel techniques through five complementary work- packages. Our goal is to design and validate new tools available to a large community of clinicians and researchers working in this field, and to characterize in depth genotype- functional- phenotype correllations. EELARVE Kõik eelarves toodud summad on Eurodes I. Tulud 10.03.2020 - 01.01.2021 - 01.01.2022 - 01.01.2023 - Kokku 31.12.2020 31.12.2021 31.12.2022 28.02.2023 Ülikoolile laekuv summa 75000,00 0,00 0,00 0,00 75000,00 Kokku: 75000,00 0,00 0,00 0,00 75000,00 II. Kulud 10.03.2020 - 01.01.2021 - 01.01.2022 - 01.01.2023 - Kokku 31.12.2020 31.12.2021 31.12.2022 28.02.2023 Palgafond 0,00 0,00 0,00 0,00 0,00 Töötasu 0,00 0,00 0,00 0,00 0,00 Tööjõukulud* 0,00 0,00 0,00 0,00 0,00 Stipendium 0,00 0,00 0,00 0,00 0,00 Invest. põhivarasse 0,00 0,00 0,00 0,00 0,00 Lähetuskulud 1500,00 2000,00 2000,00 500,00 6000,00 Sisseostetavad teenused 9000,00 9000,00 9000,00 3000,00 30000,00 Muud kulud 7000,00 7000,00 7000,00 3000,00 24000,00 Otsesed kulud kokku: 17500,00 18000,00 18000,00 6500,00 60000,00 Ülikooli üldfond 0,00 0,00 0,00 0,00 0,00 Valdkonna arengufond OMVMV 0,00 0,00 0,00 0,00 0,00 Instituut OMVCM 0,00 0,00 0,00 0,00 0,00 Uurimisrühm 0,00 0,00 0,00 0,00 0,00 Üldkulu eraldis kokku: 0,00 0,00 0,00 0,00 0,00 Kokku: 17500,00 18000,00 18000,00 6500,00 60000,00 *Sotsiaalmaks ja töötuskindlustus VALDKONNAD JA ERIALAD Tegevusvaldkond ja eriala (TA) Valdkond Alamvaldkond Cercs Eriala Frascati Eriala Protsent 3 - Terviseuuringud 3.7 - Kliiniline meditsiin B725 - Diagnostika 3.2 Kliiniline meditsiin Alusuuring % 20,00% Rakendusuuring % 80,00% Katse-arendustöö % 0,00% 100,00% Tegevusvaldkond ja eriala (OO) Haridus 0,00% Õppekavaarendus 0,00% Humanitaaria ja kunst 0,00% Suve(talve)kool 0,00% Sotsiaalteadused 0,00% Üliõpilas- ja õppejõuvahetus 0,00% Loodus- ja täppisteadused 0,00% Täiendusõpe 0,00% Tehnika, tootmine ja ehitus 0,00% Õppeinfrastruktuur 0,00% Põllumajandus 0,00% Muu 0,00% Tervis ja heaolu 0,00% 0,00% Teenindus 0,00% 0,00% PROJEKTI TÄITJAD Nimi Roll Osalemise periood Katrin Õunap (MVCM18 kliinilise geneetika professor) vastutav täitja 10.03.2020 - 28.02.2023 Sander Pajusalu MVCM18 (tööleping) täitja 10.03.2020 - 28.02.2023 Sanna Puusepp MVCM18 (tööleping), MV (arst-resident), MV (üliõpilane) täitja 10.03.2020 - 28.02.2023 Siiri Sarv MV (üliõpilane) täitja 10.03.2020 - 28.02.2023 Tiina Kahre MVCM18 (tööleping) täitja 10.03.2020 - 28.02.2023 PROJEKTI PARTNERID Nimi Roll Riik CERBM, IGBMC partner Prantsusmaa Hospital Universitari Vall s¿Hebron partner Hispaania Semmelweis University partner Ungari Stichting VUMC, Physiology partner Holland Tampere University Hospital juhtivpartner Soome University of Florence partner Itaalia PROJEKTI KOOSKÕLASTAJAD Vastutav täitja: Jrk Kooskõlastaja Kooskõlastaja roll Märkus Tegevuse aeg PROJEKTI FAILID Nimetus Lisaja Lisamise aeg ,Consortium Agreement TDOLS-G AUTHoRlsED Īo slcN oN BEHALF oF UNIVERSITY OF TARTU Name: Taivo Raud Function in Organization: Head of Grant Office Date 3.l.01.2020_ Signature 18 EUROOPA HARULDASTE HAIGUSTE VÕRGUSTIKU EJP RD 2019.A. TAOTLUSVOORU GRANDILEPING NR …. Eesti Vabariik, Sotsiaalministeeriumi kaudu, registrikood 70001952, asukoht Suur-Ameerika 1, 10122 Tallinn, keda esindab Sotsiaalministeeriumi põhimääruse § 9 punkti 9 alusel kantsler Marika Priske (edaspidi Ministeerium), Katrin Õunap (isikukood 46407292730) Tartu Ülikooli uurimisprojekti alusel (edaspidi Grandihoidja) ja Tartu Ülikool, registrikood 74001073, asukoht Ülikooli 18, 50090 Tartu, keda esindab rektori käskkirja no. 19 (29.12.2017) alusel Taivo Raud (edaspidi Asutus), edaspidi koos Pooled ja eraldi Pool, Lähtudes EJP RD raamkonsortsiumi lepingust, mis allkirjastati ministeeriumi poolt 30. septembril 2019, Tartu Ülikooli uurimisprojektist IDOLS-G (edaspidi Projekt) ja Projekti konsortsiumleppest (edaspidi Konsortsiumileping), mis allkirjastati Asutuse poolt 31.01.2020, sõlmisid käesoleva grandilepingu (edaspidi Leping) alljärgnevas: 1. LEPINGU ESE 1.1. Riigieelarveline toetus summas 75 000 (seitsekümmend viis tuhat) eurot (edaspidi toetus). 1.2. Asutus kasutab toetust EJP RD 2019. a. taotlusvooru ühiskonkursil osalenud ühisprojekti IDOLS-G „Improved diagnostic output in large sarcomeric genes“, mille üks osa on Tartu Ülikooli uurimisprojekt, läbiviimiseks. Toetuse kasutamise täpsem kirjeldus on toodud Projektis (Lisa 4) . 1.3. Toetuse kasutamise periood on 10.03.2020–28.02.2023. 2. TOETUSE VÄLJAMAKSMISE AEG 2.1. Toetuse väljamakse aluseks on Projekt (Lisa 4) ja Konsortsiumileping (Lisa 5). 2.2. Ministeerium kannab toetuse Asutuse arveldusarvele vastavalt Asutuse koostatud eelarvele (Lisa 1) järgnevalt: 2.2.1. 21 875 eurot mitte hiljem, kui 14 päeva pärast Ministeeriumi poolt Lepingu jõustumisest teada saamist; 2.2.2. 22 500 eurot mitte hiljem, kui 14 päeva pärast I perioodi toetuse kasutamise aruande heakskiitmist Ministeeriumi poolt vastavalt Lepingu punktile 3; 2.2.3. 22 500 eurot mitte hiljem, kui 14 päeva pärast II perioodi toetuse kasutamise aruande heakskiitmist Ministeeriumi poolt vastavalt Lepingu punktile 3. 2.2.4. 8 125 eurot mitte hiljem, kui 14 päeva pärast III perioodi toetuse kasutamise aruande heakskiitmist Ministeeriumi poolt vastavalt Lepingu punktile 3. 3. ARUANNETE ESITAMINE 3.1. Toetuse kasutamise aruandeperioodid on järgmised 3.1.1. I periood – 10.03.2020–31.12.2020; 3.1.2. II periood – 01.01.2021–31.12.2021; 3.1.3. III periood – 01.01.2022–31.12.2022; 3.1.4. IV periood – 01.01.2023–28.02.2023. 3.2. Grandihoidja esitab Ministeeriumile toetuse kasutamise aruande 20 (kahekümne) tööpäeva jooksul peale iga Lepingu punktis 3.1 toodud aruandeperioodi lõppemist. 3.3. Toetuse kasutamise aruanne esitatakse Lepingu Lisas 3 toodud vormil. 4. POOLTE KOHUSTUSED 1 4.1. Ministeerium kohustub kandma eraldatud toetuse Lepingu punktis 1.2 nimetatud Projekti läbiviimiseks Lepingu punktis 2.2 toodud maksegraafiku aluses Asutuse arveldusarvele. 4.2. Asutus kohustub: 4.2.1. andma Ministeeriumi poolt ülekantud toetuse (v.a üldkululõivu ja töötasu) Grandihoidja käsutusse igasuguse viivituseta; 4.2.2. arvestama üldkululõivu proportsionaalselt antud Projekti raames läbiviidava teadustöö kuludega; 4.2.3. võimaldama Grandihoidjal ja tema poolt juhitaval uurimisrühmal kasutada Projekti täitmiseks oma infrastruktuuri; 4.2.4. vormistama Projekti töötajad (Lisa 2) tööle vastavalt töölepingu seaduses ettenähtud nõuetele ja määrama vastavalt Grandihoidja ettepanekule Projekti palgatud töötajatele töötasu, mille suurus on kooskõlas asutusesisese või asutusesisese võrdluse võimatuse korral Eesti keskmise palgatasemega vastavasisulise töö eest, võimaldama kraadiõppuritele stipendiumite maksmist Projektist; 4.2.5. sisestama Projekti andmed Eesti Teaduse Infosüsteemi (ETIS) ja avalikustama need ühe kuu jooksul pärast Lepingu allkirjastamist; 4.2.6. informeerima Ministeeriumi kõigist asjaoludest, mis takistavad Projekti täitmist antud Asutuses; 4.2.7. Ministeeriumi kirjalikul nõudel kandma neljateistkümne (14) päeva jooksul mitte- sihtotstarbeliselt kasutatud või Projekti lõpus kasutamata jäänud toetuse osa Ministeeriumi arveldusarvele; 4.2.8. võimaldama Ministeeriumil ja tema volitatud isikutel kontrollida Asutuse ja Grandihoidja esitatud aruannete õigsust, toetuse saamise tingimuseks olevate asjaolude paikapidavust ja toetuse kasutamise sihipärasust. 4.3. Grandihoidja kohustub: 4.3.1. kasutama talle eraldatud toetust heaperemehelikult, kokkulepitud korras ja tingimustel; 4.3.2. esitama Ministeeriumile saadud toetuse kasutamise kohta aruande iga perioodi kohta vastavalt Lepingu punktile 3. Aruande tähtajaks esitamata jätmise korral on ministeeriumil õigus peatada toetuse ülekanne kuni aruande saabumiseni ja selle aktsepteerimiseni Ministeeriumi poolt; 4.3.3. Ministeeriumi kirjalikul nõudel esitama Lepingu punktis 3 toodud aruandlusperioodide kestel vahearuandeid kümne (10) tööpäeva jooksul vastavasisulise nõude saamisest; 4.3.4. Ministeeriumi kirjalikul nõudel esitama toetuse arvelt kulutuste tegemist tõendavate algdokumentide koopiad viie (5) tööpäeva jooksul vastavasisulise nõude saamisest; 4.3.5. arvestama Ministeeriumi poolt kirjalikult tehtud märkustega ja antud juhistega, juhistega mittenõustumisel (sh kui Grandihoidja leiab, et need ei ole kooskõlas Lepinguga) on Grandihoidjal õigus esitada kirjalik vastuväide; 4.3.6. viivitamatult teatama Ministeeriumile: 4.3.6.1. asjaoludest, mis takistavad Grandihoidjal Lepingu täitmist; 4.3.6.2. Lepingu Lisade muutmise vajalikkusest; 4.3.6.3. Lepingu täitmisel esinevatest muudest probleemidest; 4.3.7. nimetama Ministeeriumi ja Lepingu esemes kirjeldatud tegevuse toetajana kõigis asjakohastes trükistes (artiklid, raamatud, muud trükised jne) ja avalikel esinemistel, 2 kasutades võimalusel Ministeeriumi logo vastavalt valitsusasutuste ühise visuaalse identiteedi stiilijuhistele ja EJP RD logo; 4.3.8. lõpetama Ministeeriumi või EJP RD soovil vastava sümboolika edasise kasutamise; 4.3.9. juhul, kui Projekti täitmisel korraldatakse inimuuringuid või loomkatseid, esitama Ministeeriumile inimuuringute eetikakomitee või loomkatsete läbiviimise loakomisjoni positiivse otsuse hiljemalt 10 (kümme) tööpäeva enne inimuuringute või loomkatsete algust. 5. VASTUTUS 5.1. Pooled täidavad oma kohustusi nõuetekohaselt, mõistlikult, heas usus, hoolsalt ning arvestades häid tavasid ja praktikat. 5.2. Pooled vastutavad oma kohustuste süülise mittetäitmise eest, kui täitmisest keeldumise õigus ei tulene Lepingust või seadusest. 5.3. Pool teatab teistele Pooltele Lepingu rikkumisest, kirjeldades rikkumist piisavalt täpselt kolmekümne (30) päeva jooksul arvates päevast, millal sai teada või pidi teada saama lepingu rikkumisest. 5.4. Lepingus sätestatud kohustuste mittetäitmise või mittenõuetekohase täitmise korral on Ministeeriumil õigus esitada toetuse saajale nõue rikkumise kõrvaldamiseks, andes Asutusele rikkumise kõrvaldamiseks mõistliku tähtaja. 5.5. Lepingu olulise rikkumise esinemisel, sh kui Asutus ei kõrvalda rikkumist selleks antud tähtaja jooksul või ei teata sama tähtaja jooksul rikkumist objektiivselt vabandavatest asjaoludest, on Ministeeriumil õigus Leping ühepoolselt erakorraliselt lõpetada, teavitades sellest vastava kirjaliku avaldusega Asutust. 5.6. Asutuse poolt Lepingust tulenevate kohustuste mittetäitmisel või mittenõuetekohasel täitmisel on Ministeeriumil õigus nõuda toetuse saajalt leppetrahvi tasumist kuni 10% (kümne protsendi) ulatuses toetusest ning vastavalt Ministeeriumi äranägemisele kogu toetuse või selle osa tagastamist. Asutus tagastab toetuse (või selle osa) ja tasub leppetrahvi 10 (kümne) tööpäeva jooksul arvates Ministeeriumi vastavasisulise nõude kättesaamisest. 5.7. Lepingust tulenevate kohustuste täitmata jätmise või mittekohase täitmisega teisele Poolele tekitatud otsese varalise kahju eest kannavad Pooled täielikku vastutust selle kahju täies ulatuses. 5.8. Lepingust tulenevate kohustuste mittetäitmist või mittenõuetekohast täitmist ei loeta Lepingu rikkumiseks, kui selle põhjuseks oli vääramatu jõud. Vääramatu jõuna käsitavad pooled võlaõigusseaduse § 103 lõikes 2 nimetatud asjaolusid. Pool, kelle tegevus lepingujärgsete kohustuste täitmisel on takistatud vääramatu jõu asjaolude tõttu, on kohustatud sellest kohe teisele poolele kirjalikku taasesitamist võimaldavas vormis teatama. Vääramatu jõu asjaolude ilmnemisel pikeneb Lepingu lõpptähtaeg nimetatud asjaolude esinemise perioodi võrra. Pool peab vääramatu jõu asjaolude äralangemisel asuma Lepingut täitma. Kui vääramatu jõu asjaolude tõttu on poole Lepingust tulenevate kohustuste täitmine takistatud enam kui 60 (kuuskümmend) kalendripäeva järjest, võib kumbki Pool Lepingu lõpetada. 5.9. Pooled ei vastuta kohustuste täitmata jätmise eest, kui Lepingu mittekohase täitmise põhjustab teine Pool oma Lepingust tulenevate kohustuste täitmata jätmisega. 6. VAIDLUSTE LAHENDAMINE 6.1. Lepingust tulenevad vaidlused lahendatakse eelkõige vastastikusel mõistmisel põhinevate ja avalikke huve arvestavate läbirääkimiste teel. 6.2. Kui läbirääkimised ei anna tulemusi, lahendatakse vaidlus Harju Maakohtus. 3 7. LEPINGU KEHTIVUS JA LEPINGUST TAGANEMINE 7.1. Leping jõustub hetkel, kui Lepingu pooled on sellele alla kirjutanud, ja kehtib, kuni pooled on kõik Lepingust tulenevad kohustused täitnud. 7.2. Pooltel on õigus Leping omavahelisel kirjalikul kokkuleppel igal ajal lõpetada. 7.3. Pooltel on õigus Lepingust ühepoolselt taganeda, teatades vastavast soovist teisele poolele vähemalt kolmkümmend (30) päeva ette. 7.4. Pool võib Lepingust taganeda, kui teine Pool on Lepingust tulenevat kohustust oluliselt rikkunud ning ei ole seda kõrvaldanud mõistliku tähtaja jooksul. 7.5. Lepingu lõpetamisel punktides 7.2-7.5 juhtudel tagastab Asutus kasutamata jäänud toetuse Ministeeriumile 10 (kümne) tööpäeva jooksul peale Lepingu lõppemist. 7.6. Lepingu lõppemine ei vabasta Pooli lepingu olemusest ja teise Poole huvist tulenevatest kohustustest. 8. Volitatud esindajad 8.1. Ministeeriumi esindajaks Lepingu täitmisega seotud küsimustes on: Angela Ivask, tel. 626 9735, e-post [email protected], või teda asendav isik. 8.2. Asutuse esindajaks Lepingu täitmisega seotud küsimustes on: Grandihoidja Katrin Õunap, tel 731 9490, e-posti aadress [email protected]. 9. LEPINGU DOKUMENDID 9.1. Leping koosneb käesolevast Lepingust koos selle Lisadega ja pärast Lepingu sõlmimist sellest tehtud muudatustest, mis vormistatakse Lepingu lisana, mis on Lepingu lahutamatuteks osadeks ning moodustavad koos Lepinguga ühtse tervikliku Poolte vahel. 9.2. Lepingule on allkirjastamise hetkel lisatud alljärgnevad Lisad: 9.2.1. Lisa 1 – Pojekti eelarve aastate kaupa 9.2.2. Lisa 2 – Projekti täitjate nimekiri; 9.2.3. Lisa 3 – Toetuse kasutamise aruande vorm; 9.2.4. Lisa 4 – Tartu Ülikooli uurimisprojekt IDOLS-G; 9.2.5. Lisa 5 – IDOLS-G projekti konsortsiumileping. 9.3. Lepingu osaks on lisaks käesolevatele Lepingule ja selle Lisadele muud kokkulepped, mis sõlmitakse Lepingu sõlmimise ajal või pärast Lepingu sõlmimist ning milles sätestatakse seosed Lepinguga. Pooled kinnitavad, et sellised kokkulepped moodustavad koos Lepinguga ühtse tervikliku kokkuleppe Poolte vahel. 10. LÕPPSÄTTED 10.1. Lepinguga reguleerimata küsimustes lähtuvad pooled Eesti Vabariigis kehtivatest õigusaktidest. 10.2. Leping on koostatud eesti keeles, elektroonselt ja allkirjastatud digitaalselt. 11. POOLTE REKVISIIDID JA ALLKIRJAD 11.1. Ministeerium: Sotsiaalministeerium Aadress: Suur-Ameerika 1, Tallinn Tel: 626 9301 Faks: 626 9209 E-post: [email protected] 11.2. Grandihoidja: Katrin Õunap Aadress: L. Puusepa 2, 50406, Tartu 4 Tel: 731 9490 E-post: [email protected] 11.3. Asutus: Tartu Ülikool Aadress: Lossi 3, 51003 Tartu Tel: 737 6193 E-post: [email protected] Arveldusarve: EE281010102000234007 /allkirjastatud digitaalselt/ /allkirjastatud digitaalselt/ /allkirjastatud digitaalselt/ 5 Euroopa Haruldaste Haiguste Võrgustiku EJP RD 2019.a. Taotlusvooru Grandileping nr … Lisa 1 Pojekti eelarve aastate kaupa 10.03.2020- 01.01.2021- 01.01.2022- 01.01.2023- Kogueelarve 31.12.2020 31.12.2021 31.12.2022 28.02.2023 Töötasud ja sellega seotud 0 0 0 0 0 maksud (k.a stipendiumid) Põhivara 0 0 0 0 0 Lähetused 1 500 2 000 2 000 500 6 000 Muud kulud (töömaterjalid 16 000 16 000 16 000 6 000 54 000 ja alltöövõtt) Üldkululõiv 4 375 4 500 4 500 1 625 15 000 Kokku 21 875 22 500 22 500 8 125 75 000 6 Euroopa Haruldaste Haiguste Võrgustiku EJP RD 2019.a. Taotlusvooru Grandileping nr … Lisa 2 Projekti põhitäitjate ja projekti täitmisele kaasatud kraadiõppurite nimekiri. Perekonnanimi Eesnimi Ametikoht Koormus Kavandatud töötasu projektis (koos maksudega) või stipendium Puusepp Sanna doktorant 0 eurot Sarv Siiri doktorant 0 eurot Töötasu kokku 0 eurot 7 Euroopa Haruldaste Haiguste Võrgustiku EJP RD 2019.a. Taotlusvooru Grandileping nr … Lisa 3 SOTSIAALMINISTEERIUM Suur-Ameerika 1 10122 Tallinn TOETUSE KASUTAMISE ARUANNE 20__. a kohta Asutus: Tartu Ülikool Grandihoidja: Katrin Õunap Projekti nimetus: Tartu Ülikooli projekt IDOLS-G Kulude aruanne: Kogueelarve Täitmine Täitmine projekti Täidetud kogu 20_ algusest eelarvest (%) Töötasud ja sellega seotud maksud (k.a stipendiumid) Põhivara Lähetused Muud kulud Üldkululõiv Kokku 20__. a tegevuste kirjeldus (vähemalt 4000 tähemärki): ______________________________ _________________________________________ Grandihoidja (allkiri, kuupäev) Asutuse esindaja (nimi, allkiri, kuupäev) 8 Consortium Agreement IDOLS-G Consortium Agreement PROJECT TITLE Improved diagnostic output in large sarcomeric genes ACRONYM IDOLS-G 1 Consortium Agreement IDOLS-G CONSORTIUM AGREEMENT related to the project “Improved diagnostic output in large sarcomeric genes” BETWEEN: 1. Samfundet Folkhälsan i svenska Finland rf, Folkhälsan Research Center, located in Helsinki, Topeliuksenkatu 20, 00250 – FINLAND, duly represented by Prof. Anna-Elina Lehesjoki, Director of the Folkhälsan Research Center, hereinafter referred as ´FHRC´; 2. UNIVERSITY OF FLORENCE, Department of Biology, having seat in Florence, Piazza San Marco 4, 50121 – ITALY, duly represented by Prof. David Caramelli, Director of Department; hereinafter referred as ´UNIFI-BIO´; 3. The Institute de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC) located at the Centre Européen de Recherche en Biologie et Médecine (CERBM) 1 rue Laurent Fries, 67404 Illkirch, FRANCE, duly represented by its Director, Prof Alain Beretz. Research, hereinafter referred as ´IGBMC- CERBM´; 4. Semmelweis University, located in Budapest, Üllői út 26, 1085 - HUNGARY, duly represented by …,hereinafter referred as ´SEMMELWEIS´; 5. Hospital Universitari Vall d'Hebron, located in Barcelona, Passeig de la Vall d'Hebron 119, 08035 – SPAIN, duly represented by …, hereinafter referred as ´VALL-HEBRON´; 6. VU UNIVERSITY MEDICAL CENTER, a constituent part of VU-VUmc Foundation, established at De Boelelaan 1105, 1081 HV, Amsterdam, The Netherlands, in this matter duly represented by prof. dr. H. Brug, Dean of Faculty and Member of the Executive Board, hereinafter referred to as ´VUmc´; 7. UNIVERSITY OF TARTU, located in Tartu, Ülikooli 18, 50090 – ESTONIA, duly represented by Taivo Raud, Head of Grant Office, hereinafter referred as ´UNITARTU´; 8. KING´S COLLEGE LONDON, located in London, Strand WC2R 2LS – UNITED KINGDOME, duly represented by… hereinafter referred as ´COLLEGE´; 9. Lihastautiliitto ry, located in Turku, Läntinen Pitkäkatu 35, 20100 – FINLAND, duly represented by Eija Eloranta. President, hereinafter referred as ´LIHASTAUTILIITTO´ hereinafter, jointly or individually, referred to as ”Research Partners” or ” Research Partner”, ”Parties” or ” Party” - WHEREAS the Parties, having considerable excellence in the field concerned, have, as a consortium, submitted a proposal for a research project entitled ´Improved diagnostic output in large sarcomeric genes´. - WHEREAS the research project has been selected for financing. - WHEREAS the Parties wish to specify binding commitments among themselves. the Parties have agreed as follows: 2 Consortium Agreement IDOLS-G 1. DEFINITIONS “Access Rights” means licenses and rights to use Foreground and/or Background under the terms and conditions set out in this Agreement. “Agreement” means this consortium agreement including all annexes attached to it. “Allocated Work” means the research and the related activities allocated to each Research Partner in accordance with the Project Plan. “Background” means any information, techniques, Know-how, data, software and materials regardless of the form or medium in which they are disclosed or stored – including the relevant Intellectual Property – that are owned by a Party prior to the commencement of the Project and that are provided by a Party to a Party for use in the Project whether before or after the Effective Date. “Confidential Information” means all and any information in whatever form or mode of transmission, which is disclosed by a Party (the “Disclosing Party”) to any other Party (the “Recipient”) in connection with the Project during its implementation and which has been explicitly marked as “confidential”, or when disclosed orally, has been identified as confidential at the time of disclosure and has been confirmed and designated in writing within 15 days at the latest as Confidential Information by the Disclosing Party. “Consortium” means the consortium of Parties to this Agreement. “Coordinator” means Samfundet Folkhälsan i svenska Finland rf (Folkhälsan Research Center). “EJP-RD” means European Joint Programme on Rare Diseases, a research and innovation initiative of over 130 institutions from 35 countries to create a comprehensive, sustainable ecosystem allowing a virtuous circle between research, care and medical innovation “Force Majeure” means any one or more events beyond the control of the relevant Party which occur after the date of signing of this Agreement, were not reasonably foreseeable at the time of signing of this Agreement, and the effects of which are not capable of being overcome without unreasonable expense and/or unreasonable loss of time to the Party concerned. Events of Force Majeure shall include (without limitation) war, civil unrest, acts of government, natural disasters, exceptional weather conditions, breakdown or general unavailability of transport facilities, accidents, fire, explosions, and general shortages of energy. “Foreground” means any Know-how, Intellectual Property, materials, data and other information first reduced to practice or writing in the course of the Project, excluding any Background. “Intellectual Property” means all rights relating to any patent, trade name, trademark, database right, plant variety right, design, model, utility model, chip, topography of semiconductor product, neighboring right, including applications for registration of any of them made under this Agreement. "Know-how" means technical information (including, without limitation, information relating to inventions, discoveries, improvements, formulae, studies, analyses, protocols, concepts, methodologies, models, research, development and testing procedures, the results of experiments, tests and trials, manufacturing processes, techniques and specifications, quality control data, analyses, reports and submissions) that is not in the public domain and is not Intellectual Property. “National Funding Agency” means the relevant national agency that provides funds directly to a Research Partner. 3 Consortium Agreement IDOLS-G “Needed” means for the implementation of the Project: Access Rights are Needed if, without the grant of such Access Rights, carrying out the tasks assigned to the recipient Party would be impossible, significantly delayed, or require significant additional financial or human resources. For exploitation of own Foreground: Access Rights are Needed if, without the grant of such Access Rights, the exploitation of own Foreground would be technically or legally impossible. “Principal Investigator” means the main applicant of the Project Plan, Prof. B. Udd, employed at Folkhälsan Research Center, Samfundet Folkhälsan i svenska Finland rf “Project” means all the work related to the project entitled “Improved diagnostic output in large sarcomeric genes”, which is described in the Project Plan. “Project Period” Parties explicitly agree that the project period shall be from 1/3/2020 till 28.02.2023 and this Agreement shall have effect as from the 1/3/2020 (“Effective Date”). “Project Plan” means the final detailed project plan, including the budget, related to the Project as agreed between the Parties after submission to EJP-RD. The Project Plan is an integral part of this Agreement and is attached to this Agreement as Annex I. “Third Party” means any entity other than the Parties to this Agreement. 2 SCOPE AND PURPOSE The subject of this Agreement is to specify, with respect to the Project, the organization of the work between the Parties, to organize the management of the Project, and to define rights and obligations of the Parties. 3 IMPLEMENTATION OF THE PROJECT 3.1 Each Research Partner shall use reasonable endeavors to carry out its Allocated Work on the terms set out herein and complete the Allocated Work within the effective period of this Agreement. 3.2 Each Party undertakes to use reasonable endeavors to supply promptly to the Coordinator, all such information or documents as the Coordinator, needs to fulfill its obligations pursuant to the regulations issued by EJP-RD and/or pursuant to this Agreement. 3.3 Each Party undertakes to use reasonable endeavors to notify the Coordinator promptly of any significant delay in performance likely to affect the success of the Project. 3.4 Each Party undertakes to use reasonable endeavors to inform all Parties in the Project of relevant communications it receives from Third Parties in relation to the Project. 3.5 Each Party shall use reasonable endeavors to ensure the accuracy of any information or materials it supplies hereunder and promptly to correct any error therein of which it is notified. The recipient Party shall be entirely responsible for the use to which it puts such information and materials. 3.6 Each Party shall adhere to the timetable, actions, and outputs, as detailed in the Project Plan. 4 Consortium Agreement IDOLS-G 3.7 Each Research Partner shall provide, upon receipt of a written request, all detailed data requested by its National Funding Agency for the purposes of the proper administration of this Project. 3.8 Each Research Partner shall adhere to the rules relating to the EJP-RD grant, as set out by its National Funding Agency. Each Research Partner shall submit any technical or financial reports to its National Funding Agency, if applicable. 3.9 Each External Partner shall contribute to the Project with its in in-kind contribution needed for the implementation of the Project, as specified in the Project Plan. 3.10 Each Party shall ensure that its work on the Project complies fully with all applicable local, government and international laws, regulations and guidelines which are effective during the duration of the Agreement, including those governing health and safety, data protection, and where relevant, the use of human and animal subjects. Each Party shall secure all necessary declarations or approvals from or to the relevant research ethics committees and authorities before undertaking any part of the Project requiring declaration such declaration or approval and shall, if required, obtain properly signed informed consent and acknowledgement forms from any human subjects or their legal guardians who they will involve in the Project. 3.2 Third Parties A Party that enters into a subcontract or otherwise involves Third Parties in the Project remains solely responsible for carrying out its relevant part of the Project and shall ensure that any agreements entered into between the Party and such Third Party (including any subcontractor), contain terms and conditions no less stringent as the terms and conditions set out in this Agreement. The Party has to ensure that the involvement of Third Parties does not affect the rights and obligations of the other Parties under this Agreement. The Party subcontracting tasks within the Project will be responsible for the performance of the tasks by the subcontractor. The identity of all subcontractors and Third Parties shall be disclosed to the Coordinator. A Third Party shall not be granted Access Rights to another Party’s Foreground or Background without that Party’s prior written consent. 4 MANAGEMENT 4.1 The Principal Investigator coordinates and manages the Project and represents the Parties. 4.2 The Principal Investigator is responsible for the following tasks and functions: • Overall management of the Project. • Preparing meetings, proposing decisions and preparing the agenda of the meetings, chairing the meetings and preparing the minutes of the meetings. • Steering the scientific progress of the Project and ensuring communication, coherence and cooperation between the different work packages; • Processing all technical and administrative information into Project periodic and final reports compliant with EJP-RD requirements • Manage the administration of the Project. 5 Consortium Agreement IDOLS-G The Principal Investigator is entitled to delegate the tasks and functions to qualified staff members under his direction and supervision. 5 PROJECT FUNDING 5.1 Each Party shall bear its own costs in connection with the carrying out of the Project. 6.2 Each Research Partner shall be responsible for entering and managing funding arrangements with its National Funding Agency. 6 DISSEMINATION 6.1 Each Party is encouraged to publish in written form, oral presentation or making public in any other form (including electronic publication on the internet), hereinafter referred to as the “Publication”, the results of the Project, including but not limited to solely generated Foreground, after providing a copy of the draft Publication to the other Parties at least thirty calendar days prior to submission for publication or disclosure. 6.2 The other Parties may, by giving written notice to the Party requesting the Publication (a “Confidentiality Notice"), require the publishing Party to: (a) amend the Publication in order to remove any of its Background that is Confidential Information for the duration of the confidentiality obligation as set out in clause 8, or to remove any of its Foreground; or (b) amend the Publication if it can reasonably demonstrate that the manuscript compromises disproportionally its academic or legitimate interests. The other Party shall give such Confidentiality Notice within thirty calendar days after receipt of the draft Publication. The Confidentiality Notice shall contain specific details to be amended and the Party seeking disclosure shall delete said specific details in as far as they comprise the other Party’s Confidential Information from the Publication or amend said specific details as not to disproportionally harm the requesting Party's academic or legitimate interests. If no objection is made within the time limit stated above, the Publication is permitted. 6.3 If an objection has been raised the involved Parties shall discuss how to overcome the justified grounds for the objection on a timely basis (for example by amendment to the planned Publication before publication). The objecting Party shall not unreasonably continue the opposition if appropriate actions are performed following the discussion. In any event, any delays of a Publication shall not exceed a period of more than 90 calendar days from the date of the notification from the Party seeking disclosure. 6.4 Contributors to the results obtained through work on the Project published shall be named and accredited in the Publication in accordance with academic custom. 7 INTELLECTUAL PROPERTY 7.1 Background 7.1.1 Ownership Each Party will remain the owner and will retain control of its Background. 6 Consortium Agreement IDOLS-G Unless stated otherwise in the Project, the Parties agree to the general principle that methods, procedures, techniques, models, equipment, datasets, etc., are provided by a Party as Background and which are developed, improved upon or supplemented with a new functionality during the performance of the Project will be considered as Background belonging to the Party that owns the Background, provided that the development and/or improvement is not an expected outcome of the Project or is not inventive as such. 7.1.2 Access Rights to Background for implementation of the Project Each Party grants the other, on a needed basis, a royalty-free, non-exclusive licence to use its Background for the sole purpose of carrying out the Project. No Party may grant any sub-licence to use another Party’s Background, without a prior written permission of that Party. Each Party may identify in Annex II the Background to which it is ready to grant Access Rights, subject to the provisions of this Agreement. The owning Party may add further Background to Annex II during the term by written notice. The Parties agree that all Background not listed in Annex II shall be explicitly excluded from Access Rights. 7.1.3 Access Rights for commercialization If a Party needs Access Rights to Background for the commercial use of its Foreground, the other Party may grant that Party Access Rights on market terms and conditions as applicable in the relevant international market to be further determined in good faith at that time and insofar a Party is free to do so. The grant of such Access Rights will be valid only as and when it is the subject of a formal written agreement between the Parties. For the avoidance of doubt, a Party is not obliged to grant such Access Rights to its Background. A Party may not grant any sub- license to use another Party’s Background without a prior written permission of that Party. 7.2 Foreground 7.2.1 Ownership Foreground shall be the property of the Party whose employees, researchers, research fellows, students, or individuals equivalent to those persons make the inventive step, or the creative step (in case of non-patent Intellectual Property), carrying out the work generating that Foreground. 7.2.2 Joint Ownership Joint Foreground shall be the property of the Parties whose employees, researchers, research fellows, students or individuals equivalent to those persons have jointly generating that joint Foreground in proportion to each Party’s intellectual contribution. Where their joint Foreground cannot be ascertained, such joint Foreground shall be owned by those Parties in equal shares. The joint owners shall, within a six month period as from the date of the generation of such Foreground, make their best effort to establish a written separate joint ownership agreement regarding the allocation of ownership and terms of exercising, protecting, the division of related costs and exploiting such jointly owned Foreground Intellectual Property on a case by case basis. In the event that the joint owners fail to enter into a joint ownership agreement within the time period set out above, each of the joint owners shall be entitled to use the jointly owned Foreground and to grant non-exclusive licenses on the joint Foreground to Third Parties, without any right to sub-license, subject to the following conditions: - at least 45 days prior notice must be given to the other joint owner(s); and - fair and reasonable compensation must be provided to the other joint owner(s), unless otherwise agreed upon in writing between the joint owners. - disclosure of Foreground or granting of right to Third Parties does not unfairly prejudice the other joint owner’s rights in the Foreground. Notwithstanding the foregoing, prior notice and fair and reasonable compensation does not have to be provided to the other joint owner(s) in the event joint Foreground is used for non- 7 Consortium Agreement IDOLS-G commercial research and/or teaching purposes; such Access Rights shall at all times be granted on a royalty-free basis. The joint owners shall agree on all protection measures – if any – and the division of related cost – if any – in advance. 7.2.3 Access Rights for implementation of the Project Each Party shall have Access Rights at no charge to any Foreground for implementing its work under the Project. 7.2.4 Access Rights for non-commercial internal use Each Party shall have Access Rights at no charge to any Foreground that is to be used for educational or internal, non-commercial research purposes. These Access Rights cannot be sub- licensed to Third Parties. 7.2.5 Access Rights for commercialization If a Party needs Access Rights to Foreground for the commercial use of its Foreground, the other Party may grant that Party Access Rights on market terms and conditions as applicable in the relevant international market to be further determined in good faith at that time and insofar a Party is free to do so. The grant of such Access Rights will be valid only as and when it is the subject of a formal written agreement between the Parties. For the avoidance of doubt, a Party is not obliged to grant such Access Rights to its Foreground. 7.2.6 Access Rights for Third Parties (non-exclusive rights to permit cooperation) Notwithstanding the provisions of this section 7, each Party may enter into a technical co- operation or licensing arrangement with a Third Party in respect of its solely owned own Foreground, including, but not limited to, the carrying out of research on behalf of a Third Party. 7.2.7All requests for Access Rights shall be made in writing. 8 CONFIDENTIALITY 8.1 The Recipient hereby undertakes: - not to use Confidential Information otherwise than for the purpose for which it was disclosed; - not to disclose Confidential Information to any Third Party without the prior written consent by the Disclosing Party; - to ensure that internal distribution of Confidential Information by a Recipient shall take place on a strict need-to-know basis; and - to return to the Disclosing Party on demand all Confidential Information which has been supplied to or acquired by the Recipient including all copies thereof and to delete all information stored in a machine readable form. If needed for the recording of ongoing obligations, the Recipient may however request to keep a copy for archival purposes only. 8.2 The Recipient shall be responsible for the fulfillment of the obligations in clause 8 on the part of their employees and shall ensure that its employees remain so obliged, as far as legally possible, during and after the end of the Project and/or after the termination of employment. 8.3 The above shall not apply for disclosure or use of Confidential Information, if and in so far as the Recipient can show that: - the Confidential Information becomes publicly available by means other than a breach of the Recipient’s confidentiality obligations; 8 Consortium Agreement IDOLS-G - the Disclosing Party subsequently informs the Recipient that the Confidential Information is no longer confidential; - the Confidential Information is communicated to the Recipient without any obligation of confidence by a Third Party who is in lawful possession thereof and under no obligation of confidence to the Disclosing Party; - the Confidential Information, at any time, was developed by the Recipient completely independently of any such disclosure by the Disclosing Party; - the Confidential Information was already known to the Recipient prior to disclosure; or - the Party is required to disclose Confidential Information in order to comply with applicable laws or regulations or with a court or administrative order. If any Party becomes aware that it will be required, or is likely to be required, to disclose Confidential Information in order to comply with applicable laws or regulations or with a court or administrative order, it shall, to the extent it is lawfully able to do so, prior to any such disclosure, notify the Disclosing Party, and comply with the Disclosing Party’s reasonable instructions to protect the confidentiality of the information. 8.4 The Recipient shall apply the same degree of care with regard to the Confidential Information disclosed within the scope of the Project as with its own confidential and/or proprietary information, but in no case less than reasonable care. 8.5 Each Party shall promptly advise the other Party in writing of any unauthorized disclosure, misappropriation or misuse of Confidential Information after it becomes aware of such unauthorized disclosure, misappropriation or misuse. 8.6 The confidentiality obligations under this Agreement shall not prevent the communication of Confidential Information to the EJP-RD. 9 LIABILITY 9.1 Any and all advice, information, Background and Confidential Information made available in the context of this Project are made available "as is" and each Party understands and agrees that such advice, information, Background and Confidential Information may be experimental in nature and are made available without any representation or warranty, express or implied, including any implied warranty of merchantability, satisfactory quality or fitness for any particular purpose or any warranty that the use of the same will not infringe or violate any patent or other proprietary rights of any Third Party. Unless expressly agreed by such Party, no Party shall be deemed to have made any warranties of merchantability or fitness for any particular purpose of Foreground. 9.2 Neither Party accepts any liability or responsibility for any use by another Party of any Foreground, nor for any reliance which may be placed by that other Party on any Foreground, nor for advice or information given in connection with any Foreground. 9.3 The liability of any Party for any breach of this Agreement will not extend to indirect or consequential damages or to loss of business, loss of profit, loss of revenue or loss of contracts, provided such damage was not caused by a willful act or by gross negligence that by law cannot be limited or excluded. 9.4 In any event, the maximum liability of any Research Partner under this Agreement shall not exceed the funding received by that Research Partner of its National Funding Agency, provided such damage was not caused by a willful act or by gross negligence that by law cannot be limited or excluded. 9 Consortium Agreement IDOLS-G 9.5 Each Party shall be solely liable for any loss, damage or injury to Third Parties resulting from the performance of the said Party’s obligations by it or on its behalf under this Agreement or from its use of Foreground or Background. 9. 6 Subject to article 9.4, each Party will indemnify and keep indemnified in full and on demand each of the other Parties in connection with any and all loss, liabilities, demands, costs, expenses arising and/or suffered or incurred by any other Party as a result of or arising out of the acts and omissions of any Third Party appointed by it. 9.7 The terms of this Agreement shall not be construed to amend or limit any Party’s non- contractual liability. 10 ENTRY INTO FORCE, DURATION AND TERMINATION 10.1 An entity becomes a Party to this Agreement upon signature of this Agreement by a duly authorized representative. 10.2 Unless earlier terminated as set forth in clause 10.3 hereof, this Agreement shall continue in full force and effect for a period of 36 months after entry into force. The duration of the Project can be extended only by means of a written agreement between the Parties. 10.3 Termination 10.3.1 If a Party materially breaches its obligations according to the Agreement, the other Parties may terminate the Agreement 30 days after the breach has been brought to the breaching Party's attention without the breaching Party remedying the breach. 10.3.2 The breaching Party shall pay any additional expenses incurred by the other Parties as a direct consequence of the breach and the termination and which the other Parties have no possibility of preventing. If the Agreement is terminated as a result of clause 10.3.1, the non-breaching Parties may claim damages in accordance with the general rules of Belgian law. 10.3.3 A Party may terminate the Agreement immediately by written notice to the other Parties a) in case EJP-RD suspends or withdraws the grant. b) in the event of involuntary liquidation or suspension of payments of any of the other Parties. The Parties are obliged to inform the Coordinator immediately in writing in the event it arrives in the state of suspension of payments or involuntary liquidation. 10.3.4 Termination shall not affect any rights or obligations of a Party leaving the Consortium incurred prior to the date of termination, unless otherwise agreed between the leaving Party and the other Parties. This includes the obligation to provide all input, deliverables and documents for the period of its participation. 10.4 Force Majeure 10.4.1 No Party shall be considered to be in breach of this Agreement if such breach is caused by Force Majeure. 10.4.2 Each Party will notify the Coordinator of any Force Majeure as soon as possible. 10.4.3 The Parties shall use all reasonable endeavors to avoid or remove the causes of non performance and discuss in good faith the possibilities of a transfer of tasks affected by the event. Such discussions shall commence as soon as reasonably possible. 10.4.4 The Coordinator may upon written notice to all Parties suspend or terminate the Project due to Force Majeure, subject to the approval of, or a decision thereto by the Funding Body. 10 Consortium Agreement IDOLS-G 10.4.5 If the consequences of any Force Majeure during the duration of the Project are not overcome within two months after the notification mentioned under 10.4.2, the transfer of tasks (if any) shall be decided by the other Parties. 11 MISCELLANEOUS 11.1 No rights or obligations of the Parties arising from this Agreement may be assigned transferred or subcontracted, in whole or in part, to any Third Party without the other Parties’ prior formal approval. 11.2 In the case of legal succession, the Party concerned is obliged to transfer all duties under this Agreement to its legal successor. 11.3 Modifications, changes and extensions to this Agreement are only binding after these have been agreed upon in writing between the Partiesand signed by their duly authorized representative(s). 11.4 The invalidity or unenforceability of any particular provision of this Agreement shall not affect any other provisions therein. The Agreement shall be construed in all respects as if such invalid or unenforceable provision were omitted. In case the terms of this Agreement are in conflict with the terms of the National Funding Agencies’ funding conditions, the respective term(s) of this Agreement is/ are invalid terms and the latter shall prevail. In such a case, the Parties concerned shall be entitled to request that a valid and practicable provision be negotiated which fulfils the purpose of the original provision. 11.5 This Agreement shall be construed in accordance with and governed by the laws of Finland. 11.6 In the event of a dispute, the Parties agree that a negotiated settlement will be sought by the conflicting Parties in good faith. All disputes which may arise from the Agreement or from the execution of the Agreement and which cannot be settled amicably will be submitted to the courts in Helsinki. 11.7 The provisions relating to clauses 7, 8, 9, 11.6 and 11.7 shall survive the expiration or termination of this Agreement. 11.8 All sensitive data will be handled as detailed in the Data Management Plan (DPM) that will be drafted within 3 months after entry into force of this agreement and, however, according to the General Data Protection Regulation (GDPR, Regulation 2016/679 of the European Parliament and of the Council of 27 April 2016). 11.9 Any transfer or sharing of personal data between the parties shall be subject to a separate agreement. Thus drawn up and signed by: 11 Consortium Agreement IDOLS-G AUTHORISED TO SIGN ON BEHALF OF Samfundet Folkhälsan i svenska Finland rf - Folkhälsan Research Center Name: Anna-Elina Lehesjoki Function in Organization: Director of the Folkhälsan Research Center Date _________________________________________________ Signature _______________________________________________ 12 Consortium Agreement IDOLS-G AUTHORISED TO SIGN ON BEHALF OF UNIVERSITY OF FLORENCE - Department of Biology Name: David Caramelli Function in Organization: Director of Department Date _________________________________________________ Signature _______________________________________________ 13 Consortium Agreement IDOLS-G AUTHORISED TO SIGN ON BEHALF OF Institute de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC) Name: Alain Beretz Function in Organization: Director Date _________________________________________________ Signature _______________________________________________ 14 Consortium Agreement IDOLS-G AUTHORISED TO SIGN ON BEHALF OF Semmelweis University Name: ________________________________________________ Function in Organization: ____________________________ Date _________________________________________________ Signature _______________________________________________ 15 Consortium Agreement IDOLS-G AUTHORISED TO SIGN ON BEHALF OF Hospital Universitari Vall d'Hebron Name: ________________________________________________ Function in Organization: ____________________________ Date _________________________________________________ Signature _______________________________________________ 16 Consortium Agreement IDOLS-G AUTHORISED TO SIGN ON BEHALF OF VU UNIVERSITY MEDICAL CENTER Name: Prof. Dr. J. Brug Function in Organization: Member of the Executive Board Date _________________________________________________ Signature _______________________________________________ 17 Consortium Agreement IDOLS-G AUTHORISED TO SIGN ON BEHALF OF UNIVERSITY OF TARTU Name: Taivo Raud Function in Organization: Head of Grant Office Date _________________________________________________ Signature _______________________________________________ 18 Consortium Agreement IDOLS-G AUTHORISED TO SIGN ON BEHALF OF KING´S COLLEGE LONDON Name: ________________________________________________ Function in Organization: ____________________________ Date _________________________________________________ Signature _______________________________________________ 19 Consortium Agreement IDOLS-G AUTHORISED TO SIGN ON BEHALF OF Lihastautiliitto ry Name: Eija Eloranta Function in Organization: President Date _________________________________________________ Signature _______________________________________________ 20 Consortium Agreement IDOLS-G ANNEX I PROJECT PLAN 21 Consortium Agreement IDOLS-G ANNEX II BACKGROUND INCLUDED 22
Allikas: Sotsiaalministeerium dokumendiregister →
dokumendiregister.eeAsutusedEesti avalike dokumendiregistrite otsing · nimistu.ee andmetel